# Delova Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delova-biotech

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.delovabio.com
- Total disclosed funding: $133M
- Latest round: Series C (Jul 22, 2026)
- Investors on record: 23

## About

Based in Nanjing, China, and founded in 2017, Nanjing Delova Biotech Co., Ltd., trading as Delova Biotech, is a global biotechnology company focused on the research and development of novel drugs in the field of pain management. Its aim is to provide patients with non-opioid, long-acting, and potent analgesics. The founder and CEO of the company, Qingsong Wang, graduated from China Pharmaceutical University. The co-founder and CSO of the company, Ning Hu, graduated from the University of Southern California. In July 2026, Delova Biotech raised approximately CNY 600 million in Series C funding co-led by Jiangsu Venture Capital, Efung Capital, Oriza Holdings and Riverhead Capital, with participation from Guangzhou Pharmaceutical Capital, China Capital Management, Tailong VC, Kaiheng Capital, Guosen H&S, Guangzhou Industry Investment Holding Group, Hunan Chasing Fund Management, Boc Private Equity Firm, Guangzhou Guoju Venture Capital, Addor Capital, Zijin Venture Capital and Peakview Capital.

The company focuses on the research and development of drugs in the field of pain management, and it has laid out nearly 10 non-opioid analgesics. It has developed several independent intellectual property technology products, such as extended and controlled release injection, topical transdermal technology, and solubility enhancement technology for insoluble drugs, which cover postoperative pain, aesthetic surgery pain, multiple neuropathic pains, osteoarthritis pain, migraine, and trigeminal neuralgia. Nanjing Delova Biotech Co., Ltd. also focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, prodrug modification, etc.

The company’s revenue is generated by the development and eventual commercialization of its proprietary drug formulations. 

The Series C funding raised in July 2026 will be used to advance the clinical development and indication expansion of the company's three late-stage pipeline drugs, as well as the investigational new drug (IND) applications and clinical development of multiple innovative target-based small molecule pipelines with global competitiveness, in order to address significant unmet clinical needs globally.

## Funding rounds

- Series C, Jul 22, 2026, $89M — Oriza Holdings, Zijin Venture Capital, Guosen H&S, Efung Capital, Addor Capital, China Capital Management, Riverhead Capital, Guangzhou Guoju Venture Capital, Guangzhou Industry Investment Holding Group, Hunan Chasing Fund Management, Peakview Capital, Tailong VC, Kaiheng Capital, Jiangsu Venture Capital, Boc Private Equity Firm, Guangzhou Pharmaceutical Capital
- Series B, Apr 2, 2024, $14M — Hyfinity Investments, Peakview Capital, Zhongqi  Capital
- Series B, Mar 28, 2023, $15M — Zijin Venture Capital, Suzhou International Development Venture Capital Holding, Citic Group, Addor Capital, Dynamic Capital
- Series A, Jun 16, 2021, $16M — Legend Capital, MPC

## Investors

- Legend Capital — Series A
- MPC — Series A
- Zijin Venture Capital (https://capitalatlas.ai/funds/zijin-venture-capital) — Series B, Series C
- Suzhou International Development Venture Capital Holding (https://capitalatlas.ai/funds/suzhou-international-development-venture-capital-holding) — Series B
- Citic Group — Series B
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B, Series C
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series B
- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Series B
- Peakview Capital — Series B, Series C
- Zhongqi  Capital (https://capitalatlas.ai/funds/zhongqi-capital) — Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C
- Guosen H&S (https://capitalatlas.ai/funds/guosen-h-s) — Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series C
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series C
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series C
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series C
- Hunan Chasing Fund Management (https://capitalatlas.ai/funds/hunan-chasing-fund-management) — Series C
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series C
- Kaiheng Capital (https://capitalatlas.ai/funds/kaiheng-capital) — Series C
- Jiangsu Venture Capital (https://capitalatlas.ai/funds/jiangsu-venture-capital) — Series C
- Boc Private Equity Firm (https://capitalatlas.ai/funds/boc-private-equity-firm) — Series C
- Guangzhou Pharmaceutical Capital — Series C